{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:39:12Z","timestamp":1768286352164,"version":"3.49.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,26]]},"DOI":"10.7759\/cureus.97838","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T11:13:20Z","timestamp":1764155600000},"source":"Crossref","is-referenced-by-count":1,"title":["Drug-Induced Bullous Pemphigoid Triggered by Immune Checkpoint Inhibitor Opdualag in an Elderly Patient With Recurrent Metastatic Melanoma: A Case Report and Treatment Course With Dupilumab"],"prefix":"10.7759","author":[{"given":"Brian A","family":"Moreno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moises","family":"Lutwak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Lutwak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Kerdel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.1624","article-title":"Association of bullous pemphigoid with immune checkpoint inhibitor therapy in patients with cancer: a systematic review","volume":"158","author":"Asdourian MS","year":"2022","unstructured":"Asdourian MS, Shah N, Jacoby TV, Reynolds KL, Chen ST. Association of bullous pemphigoid with immune checkpoint inhibitor therapy in patients with cancer: a systematic review. JAMA Dermatol. 2022, 158:933-41. 10.1001\/jamadermatol.2022.1624","journal-title":"JAMA Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215451","article-title":"A retrospective, single-institution experience of bullous pemphigoid as an adverse effect of immune checkpoint inhibitors","volume":"14","author":"Shalata W","year":"2022","unstructured":"Shalata W, Weissmann S, Itzhaki Gabay S, et al.. A retrospective, single-institution experience of bullous pemphigoid as an adverse effect of immune checkpoint inhibitors. Cancers (Basel). 2022, 14:5451. 10.3390\/cancers14215451","journal-title":"Cancers (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-023-01406-4","article-title":"The latest option: nivolumab and relatlimab in advanced melanoma","volume":"25","author":"Albrecht LJ","year":"2023","unstructured":"Albrecht LJ, Livingstone E, Zimmer L, Schadendorf D. The latest option: nivolumab and relatlimab in advanced melanoma. Curr Oncol Rep. 2023, 25:647-57. 10.1007\/s11912-023-01406-4","journal-title":"Curr Oncol Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1","volume":"4","author":"Naidoo J","year":"2016","unstructured":"Naidoo J, Schindler K, Querfeld C, et al.. Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol Res. 2016, 4:383-9. 10.1158\/2326-6066.CIR-15-0123","journal-title":"Cancer Immunol Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114028","article-title":"Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors","volume":"203","author":"Ruf T","year":"2024","unstructured":"Ruf T, Kramer R, Forschner A, et al.. Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors. Eur J Cancer. 2024, 203:114028. 10.1016\/j.ejca.2024.114028","journal-title":"Eur J Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1068978","article-title":"A case report of steroid-refractory bullous pemphigoid induced by immune checkpoint inhibitor therapy","volume":"13","author":"Guan S","year":"2022","unstructured":"Guan S, Zhang L, Zhang J, Song W, Zhong D. A case report of steroid-refractory bullous pemphigoid induced by immune checkpoint inhibitor therapy. Front Immunol. 2022, 13:1068978. 10.3389\/fimmu.2022.1068978","journal-title":"Front Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007324","article-title":"Management of immune-related cutaneous adverse events with dupilumab","volume":"11","author":"Kuo AM","year":"2023","unstructured":"Kuo AM, Gu S, Stoll J, et al.. Management of immune-related cutaneous adverse events with dupilumab. J Immunother Cancer. 2023, 11:e007324. 10.1136\/jitc-2023-007324","journal-title":"J Immunother Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf208","article-title":"Dupilumab for bullous pemphigoid related to immune checkpoint inhibitors: a retrospective case series","volume":"30","author":"Nykaza I","year":"2025","unstructured":"Nykaza I, Moy A, Dusza SW, et al.. Dupilumab for bullous pemphigoid related to immune checkpoint inhibitors: a retrospective case series. Oncologist. 2025, 30:oyaf208. 10.1093\/oncolo\/oyaf208","journal-title":"Oncologist"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1613552","article-title":"Case report: dupilumab therapy for immune checkpoint inhibitor-induced bullous pemphigoid enables dual immunotherapy initiation in progressive malignant melanoma","volume":"15","author":"Gr\u00fcninger J","year":"2025","unstructured":"Gr\u00fcninger J, Lehr S, Meiss F, Rafei D, Schauer F. Case report: dupilumab therapy for immune checkpoint inhibitor-induced bullous pemphigoid enables dual immunotherapy initiation in progressive malignant melanoma. Front Oncol. 2025, 15:1613552. 10.3389\/fonc.2025.1613552","journal-title":"Front Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.738907","article-title":"Efficacy and safety of dupilumab in moderate-to-severe bullous pemphigoid","volume":"12","author":"Zhang Y","year":"2021","unstructured":"Zhang Y, Xu Q, Chen L, et al.. Efficacy and safety of dupilumab in moderate-to-severe bullous pemphigoid. Front Immunol. 2021, 12:738907. 10.3389\/fimmu.2021.738907","journal-title":"Front Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15541","article-title":"Case report: dupilumab for the treatment of bullous pemphigoid","volume":"35","author":"Wang M","year":"2022","unstructured":"Wang M, Wang J, Shi B. Case report: dupilumab for the treatment of bullous pemphigoid. Dermatol Ther. 2022, 35:e15541. 10.1111\/dth.15541","journal-title":"Dermatol Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.109788","article-title":"Nine cases of refractory bullous pemphigoid treated with dupilumab and literature review","volume":"116","author":"Liang J","year":"2023","unstructured":"Liang J, Abulikemu K, Maolidan, et al.. Nine cases of refractory bullous pemphigoid treated with dupilumab and literature review. Int Immunopharmacol. 2023, 116:109788. 10.1016\/j.intimp.2023.109788","journal-title":"Int Immunopharmacol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae403","article-title":"Real-world evaluation of the effectiveness and safety of dupilumab in bullous pemphigoid: an ambispective multicentre case series","volume":"192","author":"Planella-Fontanillas N","year":"2025","unstructured":"Planella-Fontanillas N, Bosch-Amate X, Jim\u00e9nez Ant\u00f3n A, et al.. Real-world evaluation of the effectiveness and safety of dupilumab in bullous pemphigoid: an ambispective multicentre case series. Br J Dermatol. 2025, 192:501-9. 10.1093\/bjd\/ljae403","journal-title":"Br J Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.01.089","article-title":"Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series","volume":"83","author":"Abdat R","year":"2020","unstructured":"Abdat R, Waldman RA, de Bedout V, et al.. Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series. J Am Acad Dermatol. 2020, 83:46-52. 10.1016\/j.jaad.2020.01.089","journal-title":"J Am Acad Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2503521","article-title":"Effective response to high-frequency and prolonged dupilumab therapy in severe refractory bullous pemphigoid: a case study","volume":"21","author":"Jiang X","year":"2025","unstructured":"Jiang X, Chen L, Zhu Y, Zhan S, Jin N, Cheng H. Effective response to high-frequency and prolonged dupilumab therapy in severe refractory bullous pemphigoid: a case study. Hum Vaccin Immunother. 2025, 21:2503521. 10.1080\/21645515.2025.2503521","journal-title":"Hum Vaccin Immunother"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/433393-drug-induced-bullous-pemphigoid-triggered-by-immune-checkpoint-inhibitor-opdualag-in-an-elderly-patient-with-recurrent-metastatic-melanoma-a-case-report-and-treatment-course-with-dupilumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T11:13:21Z","timestamp":1764155601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/433393-drug-induced-bullous-pemphigoid-triggered-by-immune-checkpoint-inhibitor-opdualag-in-an-elderly-patient-with-recurrent-metastatic-melanoma-a-case-report-and-treatment-course-with-dupilumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.97838","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,26]]}}}